Three weeks from now, on July 1, 2026, millions of older Americans with obesity will gain access to GLP-1 weight-loss medications through Medicare for the first time in the program's 60-year history. The Centers for Medicare and Medicaid Services announced the Medicare GLP-1 Bridge in May 2026, confirming that eligible Part D enrollees will be able to access certain GLP-1 drugs — including the obesity-specific formulations of semaglutide (Wegovy) and tirzepatide (Zepbound) — for a fixed cost of $50 per month through December 2027.
The development is historic. Under existing law, Medicare Part D cannot cover drugs prescribed solely for weight loss — a statutory prohibition that has stood since Part D's creation in 2006 and has prevented tens of millions of older Americans with obesity from accessing GLP-1 therapies through their Medicare coverage. The GLP-1 Bridge operates as a time-limited payment demonstration outside standard Part D coverage, allowing CMS to test expanding obesity medication access while Congress works on permanent legislative solutions.
What the Program Covers and Who Qualifies
The Medicare GLP-1 Bridge will cover certain GLP-1 medications when prescribed specifically for obesity treatment in eligible Medicare Part D beneficiaries. CMS has indicated the program will include Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) — the two FDA-approved GLP-1 medications with primary indications for chronic weight management.
The $50 monthly copayment is fixed and does not vary by the phase of a beneficiary's Part D benefit. Unlike standard Part D drugs, the $50 copayment will not count toward the $2,100 annual Part D out-of-pocket maximum — a design feature that KFF analysis notes is intended to contain program costs and maintain the demonstration's financial sustainability.
Beneficiaries who already receive a GLP-1 through their Part D plan for a covered Medicare indication — such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea — will continue accessing the drug through their regular Part D plan rather than through the Bridge. The Bridge is specifically for patients whose only clinical indication for a GLP-1 is obesity.
Full eligibility criteria, including any body mass index thresholds, documentation requirements, or prior authorization conditions, are expected to be communicated directly to beneficiaries through their Part D plan communications as the July 1 launch date approaches. CMS has committed to releasing additional enrollment guidance before the program goes live.
The Broader Landscape: Medicaid, TrumpRx, and the Path to Permanent Access
The Medicare GLP-1 Bridge is one part of a rapidly evolving landscape of expanded GLP-1 access that is taking shape in 2026.
The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model — a CMS voluntary demonstration for both Medicare and Medicaid — opened to state Medicaid agency participation beginning in May 2026. Under BALANCE, states can opt in to offer GLP-1 coverage for obesity through their Medicaid programs at reduced federal cost. As of January 2026, only 13 states provided Medicaid coverage for GLP-1 medications for obesity treatment — down from 16 states in 2025, largely due to budget pressure from federal funding changes.
Separately, the Trump administration in late 2025 announced pricing agreements with Novo Nordisk and Eli Lilly that will make GLP-1 medications available to cash-paying consumers through the TrumpRx program at $350 per month or below, trending down toward $245 over two years. Oral GLP-1 tablets for obesity — currently in late-stage clinical development by both companies — are expected to launch at $149 per month for a starting dose once FDA-approved.
These developments, taken together, represent the most significant structural shift in GLP-1 access in the United States since the drugs were first approved. But barriers remain. KFF polling found that 56 percent of GLP-1 users describe these drugs as difficult to afford, and one in four call them "very difficult" to afford. At $50 per month under the Bridge — and with potential further price reductions under TrumpRx and manufacturer agreements — the affordability calculus is shifting.
Why This Matters: The Scale of Obesity in Older Americans
More than 70 percent of American adults are considered to have obesity or excess weight, and the condition disproportionately affects older adults. Obesity significantly increases the risk of type 2 diabetes, cardiovascular disease, sleep apnea, kidney disease, joint disease, and certain cancers. For Medicare beneficiaries — a population that already skews toward higher chronic disease burden — the inability to access obesity pharmacotherapy has represented a meaningful gap in preventive care.
GLP-1 medications have demonstrated effects beyond weight loss that are directly relevant to Medicare's covered disease populations: reductions in cardiovascular events in patients with established heart disease (Wegovy's FDA approval for cardiovascular risk reduction), improvements in blood sugar control, reductions in sleep apnea severity, and improvements in kidney function. The Medicare GLP-1 Bridge is focused on the obesity indication, but the downstream benefits to the patients who take these drugs may extend across multiple organ systems — potentially reducing long-term Medicare costs for cardiovascular, renal, and metabolic disease management.
"These drugs have only been available for people who have wealth," HHS Secretary Robert F. Kennedy Jr. said at the November 2025 announcement of the administration's GLP-1 pricing agreements, acknowledging the access gap that has defined the era of GLP-1 medications in the United States.
The July 1 launch of the Bridge marks a meaningful, if imperfect, step toward closing that gap. Eligible Medicare beneficiaries should watch for communications from their Part D plan and speak with their physician about whether they qualify for the program.
Frequently Asked Questions
Q: When does the Medicare GLP-1 Bridge program start?
A: July 1, 2026. The program runs through December 31, 2027.
Q: Which drugs are covered under the Medicare GLP-1 Bridge?
A: Eligible medications include Wegovy (semaglutide) and Zepbound (tirzepatide) when prescribed specifically for obesity. CMS will communicate the final formulary to beneficiaries before the July 1 launch.
Q: How much will it cost?
A: $50 per month, fixed, regardless of Part D benefit phase. This copayment does not count toward the $2,100 annual Part D out-of-pocket cap.
Q: Does this apply to everyone on Medicare?
A: The Bridge applies to eligible Medicare Part D enrollees who are prescribed a GLP-1 specifically for obesity treatment. Beneficiaries already receiving a GLP-1 for diabetes, cardiovascular disease, or sleep apnea continue through their standard Part D plan.
Q: What should I do to prepare for the July 1 launch?
A: Speak with your physician about whether you are clinically eligible for GLP-1 obesity treatment. Watch for communications from your Part D plan as the launch date approaches. You can also call 1-800-MEDICARE for updated enrollment information.
